^
    CANCER:

    Chronic Lymphocytic Leukemia





    Show legend
    Group by Gene:
    Include preclinical:

    BTK inhibitor
    zanubrutinib
    ibrutinib
    		0
    BTK inhibitor
    pirtobrutinib
    acalabrutinib
    orelabrutinib
    M7583
    obinutuzumab
    rituximab
    rituximab-pvvr
    		1
    CD20 inhibitor
    rituximab-abbs
    ofatumumab
    Rixathon (rituximab biosimilar)
    rituximab / hyaluronidase
    rituximab-arrx
    2
    Bcl2 inhibitor, CD20 inhibitor
    venetoclax + rituximab
    venetoclax + obinutuzumab
    3
    PD1 inhibitor
    nivolumab
    pembrolizumab
    4
    CD52 inhibitor
    alemtuzumab
    5
    PI3Kδ inhibitor
    idelalisib
    6
    Bcl2 inhibitor
    venetoclax
    BGB-11417
    7
    Bcl2 inhibitor, BTK inhibitor
    venetoclax + ibrutinib
    8
    CD52 inhibitor, CD20 inhibitor
    rituximab + alemtuzumab
    bendamustine RTD
    		9
    Alkylating agent
    cyclophosphamide
    chlorambucil
    10
    DNA replication inhibitor
    bendamustine
    11
    PI3Kδ inhibitor, CD20 inhibitor
    rituximab + idelalisib
    idelalisib + ofatumumab
    12
    PD1 inhibitor, BTK inhibitor
    pembrolizumab + nivolumab + ibrutinib
    pembrolizumab + ibrutinib
    13
    CD19-targeted CAR-T immunotherapy
    lisocabtagene maraleucel
    14
    ROR1 inhibitor, BTK inhibitor
    ibrutinib + UC-961
    15
    IKZF1 degrader, IKZF3 degrader, BTK degrader
    NX-2127
    16
    CD19-targeted CAR-T immunotherapy, BTK inhibitor
    ibrutinib + lisocabtagene maraleucel
    obinutuzumab + acalabrutinib
    ibrutinib + rituximab
    		17
    BTK inhibitor, CD20 inhibitor
    ibrutinib + obinutuzumab
    ibrutinib + ublituximab-xiiy
    ibrutinib + rituximab + obinutuzumab
    obinutuzumab + zanubrutinib
    18
    CCR7 receptor antagonist
    CAP-100
    19
    Galectin inhibitor
    OTX-008
    20
    CD3 agonist, ROR1 inhibitor
    NVG-111
    21
    MDM2 inhibitor, BTK inhibitor
    acalabrutinib + KRT-232
    22
    PARP inhibitor
    talazoparib
    23
    T-lymphocyte cell therapy
    T-lymphocyte cell therapy
    FCR
    EPOCH-R
    iFCR
    PCR
    		24
    Chemotherapy
    BR
    R-CHOP
    R-CVAD
    OFAR
    iFCG
    25
    CAR-T immunotherapy
    CAR-T immunotherapy
    26
    ATR inhibitor
    ATR inhibitor
    27
    BTK inhibitor, Chemotherapy
    BR + ibrutinib
    28
    PI3Kδ inhibitor, Chemotherapy
    BR + idelalisib
    29
    PI3Kγ inhibitor, PI3Kδ inhibitor
    duvelisib
    30
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, CD20 inhibitor
    rituximab + lenalidomide
    31
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
    lenalidomide
    32
    DNA replication inhibitor, CD20 inhibitor
    CD20 inhibitor + bendamustine
    33
    SIK3 inhibitor, PI3K inhibitor, PI3Kγ inhibitor, PI3Kδ inhibitor
    RP6530
    34
    SYK inhibitor, CD20 inhibitor
    obinutuzumab + GS-9973
    35
    Bcl2 inhibitor, BTK inhibitor, CD20 inhibitor
    venetoclax + ibrutinib + obinutuzumab
    venetoclax + obinutuzumab + acalabrutinib
    36
    CD3 agonist, CD20 inhibitor
    epcoritamab-bysp
    37
    Casein kinase I epsilon inhibitor, PI3Kδ inhibitor, CD20 inhibitor
    umbralisib + ublituximab-xiiy
    38
    TNFα inhibitor, CD19 inhibitor, IL-12 inhibitor, IL-6 inhibitor
    lenalidomide + tafasitamab-cxix
    39
    PI3Kγ inhibitor, Bcl2 inhibitor, PI3Kδ inhibitor
    venetoclax + duvelisib
    40
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    41
    DNMT inhibitor
    decitabine
    42
    HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    chidamide
    43
    HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, BTK inhibitor, AKT inhibitor, HDAC3 inhibitor
    ibrutinib + chidamide
    44
    DNMT inhibitor, BTK inhibitor
    ibrutinib + decitabine
    45
    ROR1-targeted antibody-drug conjugate, Microtubule inhibitor
    MK-2140
    46
    DNA synthesis inhibitor
    fludarabine IV
    47
    MDM2 inhibitor
    RG7388
    48
    NF-κB inhibitor
    DC-1-192
    49
    CCR7-targeted antibody-drug conjugate, Microtubule inhibitor
    JBH492
    50
    NRF2 inhibitor
    brusatol
    51
    PI3Kδ inhibitor, BTK inhibitor
    ibrutinib + idelalisib
    52
    AMPK inhibitor
    Compound C
    53
    Phospholipase A2 inhibitor, Immunomodulator
    hydroxychloroquine
    54
    ULK1 inhibitor, ULK2 inhibitor
    MRT68921
    55
    ITK inhibitor, BTK inhibitor
    SNS-062
    56
    Bcl2 inhibitor, MELK inhibitor
    venetoclax + OTS167
    57
    NRF2 inhibitor, BTK inhibitor
    ibrutinib + brusatol
    58
    MEK inhibitor, Bcl2 inhibitor
    venetoclax + trametinib
    59
    Menin-MLL inhibitor
    BMF-219
    60
    MYC inhibitor
    GT19077
    61
    ClpP agonist, GPR132 agonist
    ONC212
    62
    SYK inhibitor
    GS-9973
    63
    Casein kinase I epsilon inhibitor, PI3Kδ inhibitor
    umbralisib
    64
    MCL1 inhibitor
    S63845
    No biomarker
    TP53 mutation
    TP53 mutation + Chr del(17p)
    TP53 wild-type
    TP53 deletion
    TP53 mutation + Chr del(11q)
    IGH mutation
    IGH mutation + Chr del(11q)
    IGH mutation + Chr del(13q)
    IGH mutation + Chr del(8p)
    BIRC3 mutation
    BRAF mutation
    IGLL5 mutation
    BTK C481
    BTK L528W + BTK C481
    BTK mutation
    BTK C481R
    BTK C481S
    BTK T474I
    BTK C481R + BTK L528W
    BRAF mutation + RAS mutation
    BTK C481S + BTK R665W + BTK L845F + BTK S707Y
    BTK R665W
    BTK C481Y
    CD20 positive
    MRD4 negative
    SF3B1 mutation
    ATM mutation
    CD19 positive
    ALK positive
    PRDM1 mutation
    BCL2 mutation
    CCR7 expresion
    PLCG2 mutation
    LGALS1 overexpression + LAG3 overexpression
    CXCR4 overexpression
    CCR7 overexpression
    BCL2 N103Y
    BCL2 N103E
    BCL2 N107_N110dup
    BCL2 V156N
    Chr del(11q) + ATM mutation
    BCL2 D103Y
    BCL2 G101V
    Chr del(13q) + Chr del(11q) + SF3B1 mutation
    Chr del(17p)
    Chr del(11)(q22.3)
    Chr del(13q)
    Chr del(11q)
    Chr del(13)(q14)
    TS 12
    Chr del(17)(p13.1)
    Chr del(17p) + Chr del(11q)
    LPL deletion + TP53 deletion
    Chr del(17)(p13)
    EP300 mutation + Chr del(8p)
    MLL2 mutation + Chr del(8p)
    EIF2A mutation + Chr del(8p)
    B2M elevation
    ID3 underexpression
    POT1 mutation
    BCL2L1 overexpression
    ATM mutation + IGH mutation
    MCL1 overexpression
    NOTCH1 mutation
    Chr amplification(11)(q23)
    TAp63 overexpression
    PTEN underexpression
    miR-543 overexpression
    miR-494 overexpression
    miR-495 overexpression
    WNT5A expression
    Chr del(8p)
    BCL2 G101V + SF3B1 mutation
    ASXL1 mutation
    IGLV3 21R110
    MYC-IGH fusion
    KRAS G12A
    KEAP1 expression
    LY9 expression
    NFE2L2 expression
    ATM deletion + SF3B1 mutation
    KMT2D mutation
    ROR1 positive
    FAS overexpression
    TNFRSF1B overexpression
    TNFSF10 overexpression
    MAP2K1 overexpression
    ITGA4 negative
    CD69 overexpression
    BCL2A1 overexpression
    TRAF1 overexpression
    PTBP1 overexpression
    ITGA4 overexpression
    BTK C481S + PLCG2 D1140N
    BTK C481S + PLCG2 D1140G
    BTK C481S + PLCG2 L845F
    CXCL13 elevation